Back to results
US 2026/0069674 A9Published application
Piv5-based covid-19 vaccine
AssigneeUniversity of Georgia Research Foundation, Inc.
InventorBiao He
Life of this patent
Estimating the term…
Abstract
The present invention provides constructs of the parainfluenza virus type-5 (PIV5) virus expressing the SARS-CoV-2 envelope spike (S) protein for use as safe, stable, efficacious, and cost-effective vaccines against COVID-19.
Claims20
A viral expression vector comprising a parainfluenza virus 5 (PIV5) genome comprising a heterologous nucleotide sequence expressing a heterologous polypeptide, wherein the heterologous polypeptide comprises a coronavirus spike (S) protein.
Dependencies are inferred from the claim text.